🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Entero Healthcare Solutions Limited ENTERO NSEPHARMA

Healthcare · Medical Distribution · India
https://www.enterohealthcare.com
Company Profile ↓
₹1,827.60
+54.63% 1Y
Mkt Cap₹7,952.06 Cr
P/E83.99
P/B3.20
52W High₹1,848.00
52W Low₹949.20
Book Value₹388.09
EPS (TTM)₹21.76

Company Overview

Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products in India. The company offers a range of pharmaceuticals and other healthcare products to retail pharmacies and healthcare practitioners; and healthcare products, including pharmaceutical and nutraceutical products and vaccines; medical devices, such as orthopaedic implants and coronary stents; and hospital consumables comprising examination and surgical gloves, syringes, needles, and sutures to hospitals and clinics. It also provides private label products under the Entero Surgicals private label, such as monitoring devices, nursing and rehabilitation products, and consumables; commercial solutions; and healthcare product distribution solutions, including imports, central warehousing, redistribution, last mile delivery, and connection with the pharmacies, hospitals, and clinics. The company was incorporated in 2018 and is based in Mumbai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 365.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 25.7% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹6,540.06 Cr (+29.1% YoY); net profit ₹115.04 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +29.1%, earnings +21.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 25.7%, profit CAGR 365.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:25.70%
1 Year:29.11%

Compounded Profit Growth

5 Years:365.14%
1 Year:21.33%

Stock Price Performance

1 Year:+54.63%
6 Months:+74.56%
3 Months:+59.30%
1 Month:+47.09%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 98% of range
₹949.20 ₹1,848.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)82.00 · Overbought
Price Performance
1M+47.09%
3M+59.30%
6M+74.56%
1Y+54.63%
Valuation vs Sector

P/E of 83.99 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 25.7% over 5 years.
  • Profit CAGR of 365.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 84.0.
  • RSI at 82 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
83.99
Industry PE
41.64
Forward P/E
33.15
PEG Ratio
-
Book Value
₹388.09
Price to Book
3.20
P/S
0.82
EV/EBITDA
24.75
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
25.70%
Profit 5Y
365.14%
Revenue (YoY)
29.11%
Earnings (YoY)
21.33%

Profitability & Returns

ROCE
11.35%
ROE
6.81%
ROA
3.20%
Profit Margin
1.76%
Op Margin
3.41%
Gross Margin
9.62%
EPS (Latest Qtr)
₹6.43
EPS (TTM)
₹21.76

Balance Sheet & Liquidity

Debt/Equity
0.40
Quick Ratio
1.05
Current Ratio
1.58
Debt
₹677.15 Cr
Total Assets
₹3,600.26 Cr
Current Assets
₹2,508.44 Cr
Working Capital
₹920.87 Cr

Ownership

Promoter Holding
65.92%
Chg in Prom Hold
-1.04%
FII / Inst Holding
21.43%
Chg in FII Hold
8.98%

Financial Snapshot

Enterprise Value
₹7,952.06 Cr
Total Revenue (TTM)
₹6,540.06 Cr
EBITDA
₹271.67 Cr
Free Cash Flow
₹28.66 Cr
Operating Cash Flow
₹96.20 Cr
Shares Outstanding
₹4.35 Cr
Gross Margin
9.62%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ENTERO Entero Healthcare Solutions Limited NSEPHARMA 1,827.60 83.99 ₹7,952.06 Cr 0.00% 11.35% 6.81% 25.70% 365.14%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 887.00 Cr899.00 Cr996.00 Cr993.00 Cr1,034.00 Cr1,097.00 Cr1,301.00 Cr-1,339.06 Cr1,403.82 Cr1,570.95 Cr1,706.52 Cr1,909.93 Cr
Cost of Revenue --------1,208.29 Cr1,264.25 Cr1,410.15 Cr1,533.93 Cr1,702.51 Cr
Gross Profit --------130.77 Cr139.57 Cr160.80 Cr172.59 Cr207.42 Cr
Operating Expenses 867.00 Cr873.00 Cr968.00 Cr964.00 Cr1,005.00 Cr1,067.00 Cr1,258.00 Cr-90.35 Cr98.37 Cr108.57 Cr114.62 Cr136.17 Cr
Operating Income 13.00 Cr20.00 Cr23.00 Cr23.00 Cr22.00 Cr23.00 Cr35.00 Cr-40.42 Cr41.20 Cr52.23 Cr57.98 Cr71.25 Cr
EBITDA 20.00 Cr26.00 Cr29.00 Cr29.00 Cr29.00 Cr30.00 Cr42.00 Cr-56.21 Cr55.90 Cr66.86 Cr64.21 Cr90.05 Cr
Interest Expense 13.00 Cr14.00 Cr18.00 Cr16.00 Cr17.00 Cr10.00 Cr11.00 Cr-10.49 Cr10.66 Cr12.40 Cr14.01 Cr17.31 Cr
Pretax Income 1.00 Cr7.00 Cr7.00 Cr8.00 Cr14.00 Cr27.00 Cr35.00 Cr-37.23 Cr36.36 Cr44.62 Cr40.40 Cr57.95 Cr
Tax Provision 4.90 Cr42.00 L1.61 Cr1.28 Cr-7.84 Cr6.75 Cr8.75 Cr-5.80 Cr6.13 Cr8.03 Cr6.52 Cr12.82 Cr
Net Income -4.00 Cr6.00 Cr5.00 Cr7.00 Cr21.00 Cr21.00 Cr26.00 Cr-25.69 Cr27.80 Cr31.60 Cr27.63 Cr28.01 Cr
Diluted EPS -9.0515.183.194.224.824.625.43-5.906.387.256.346.43

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,350.00 Cr1,773.00 Cr-3,293.14 Cr3,888.16 Cr5,065.48 Cr6,540.06 Cr
Cost of Revenue ---3,031.86 Cr3,570.35 Cr4,609.47 Cr5,910.83 Cr
Gross Profit ---261.28 Cr317.81 Cr456.01 Cr629.23 Cr
Operating Expenses 1,326.00 Cr1,758.00 Cr-221.51 Cr230.98 Cr313.90 Cr406.08 Cr
Operating Income 11.00 Cr-1.00 Cr-39.77 Cr86.83 Cr142.11 Cr223.15 Cr
EBITDA 23.00 Cr15.00 Cr-64.95 Cr121.05 Cr206.97 Cr271.67 Cr
Interest Expense 13.00 Cr20.00 Cr-44.40 Cr60.48 Cr37.53 Cr49.04 Cr
Pretax Income 4.00 Cr-11.00 Cr--3.69 Cr35.55 Cr138.74 Cr179.34 Cr
Tax Provision 2.68 Cr-4.62 Cr-7.42 Cr-4.24 Cr31.30 Cr33.50 Cr
Net Income 1.00 Cr-15.00 Cr--11.56 Cr39.11 Cr94.82 Cr115.04 Cr
Diluted EPS 93.81-1,550.90-6.88-2.6610.8121.76-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 749.00 Cr836.00 Cr-1,308.73 Cr2,344.97 Cr2,702.51 Cr3,600.26 Cr
Current Assets ---1,023.17 Cr2,010.97 Cr2,075.71 Cr2,508.44 Cr
Cash & Equivalents ---25.36 Cr147.65 Cr229.28 Cr146.88 Cr
Inventory ---341.63 Cr421.15 Cr659.78 Cr841.68 Cr
Receivables ---514.88 Cr615.40 Cr830.36 Cr1,212.44 Cr
Total Liabilities ---711.07 Cr703.59 Cr932.16 Cr1,847.72 Cr
Current Liabilities ---623.96 Cr601.94 Cr845.02 Cr1,587.57 Cr
Long Term Debt ---31.07 Cr45.54 Cr0122.56 Cr
Total Debt 603.00 Cr720.00 Cr-437.76 Cr337.97 Cr385.23 Cr677.15 Cr
Total Equity -15.90 Cr-31.90 Cr-595.03 Cr1,638.06 Cr1,724.14 Cr1,688.61 Cr
Shares Outstanding ---4.35 Cr4.35 Cr4.35 Cr4.35 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -37.00 Cr-69.00 Cr--45.31 Cr-36.61 Cr-76.86 Cr96.20 Cr
Investing Cash Flow -203.00 Cr-31.00 Cr--48.59 Cr-705.12 Cr219.80 Cr-303.06 Cr
Financing Cash Flow 217.00 Cr89.00 Cr-72.76 Cr862.94 Cr-73.66 Cr123.66 Cr
Capital Expenditure -44.00 Cr-9.00 Cr--5.52 Cr-5.42 Cr-11.31 Cr-67.54 Cr
Free Cash Flow -81.00 Cr-78.00 Cr--50.83 Cr-42.03 Cr-88.18 Cr28.66 Cr
Net Change in Cash -23.00 Cr-11.00 Cr--21.15 Cr121.21 Cr69.28 Cr-83.20 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---7.9%8.2%9.0%9.6%
Operating Margin % 0.8%-0.1%-1.2%2.2%2.8%3.4%
Net Margin % 0.1%-0.8%--0.4%1.0%1.9%1.8%
ROE % -6.3%47.0%--1.9%2.4%5.5%6.8%
ROCE % ---5.8%5.0%7.7%11.1%

Shareholding Pattern

Insiders
65.92%
Institutions
21.43%
Public Float
62.90%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ENTERO

Google News Sun, 06 Sep 2026

Entero Healthcare Solutions allots ESOPs, revises director tenure - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNak44Rl9FUlY3YjdqbFJrQUQ1LWlaSFA5TUt0aDJUSldidWJkTkFycENqTW9LSzNORmVuQXZ5WEk3MGM3R0N5NHRrMWdYR1JwMkJJSzdPVWpSdExLamlfTE9ZTXRTYzBrU0h5LUc2eWl5d0N0Unl5VFhxd24ycEh0akNISWxyYnFFa0p4em…

Google News Mon, 24 Aug 2026

3 India Stocks With Steady Cash Flow That Deserve A Closer Look - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQR3VZRnlpNE9MUEVOVGs2bFBVOUVQdkl6TDlKQjl3R2QzazBXSmJBRlpxS29NNUNta3VubVVlVTkyaS1vbFlZNTdZNTBxWTlrRkhmNDlqT2dtbXRENFM3bWp2YW5vd2MwU2l6aGNtTU93RHJEWGNULUMyZUJoVmpzVGhwVDdBM2JvSEl3c0…

Google News ue, 25 Aug 2026

News by CNBC TV18 on TradingView, 2026-08-25 — cnbctv:5bce89972094b:0 - TradingView

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBscGRpUzdKSFVqOVdvbi13RkIwSmdyUHRyQ085VzFPbUJqTHNUOVIzQ0dZQ2R2eTF4LVdHUVBBZmsxZGFuUHk1a0FfWXlFeW1SRUNyM2o2cDNEV3NaSTZjck5fbTgxWlE?oc=5" target="_blank">News by CNBC TV18 on Trading…

Google News Mon, 24 Aug 2026

Prashant Jain-backed 3P Investment buys 2.5% Stake in Entero Healthcare; Amansa sells over Rs 47 crore... - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMiqgJBVV95cUxNdXdlemh2djFfWE82RjgtR2dfZ1ZFQXM5VjBjbWNSMVlsclNGaHJ4bW5JX2JUSDRkOFMxMmhsbFZSTWk3a2F1N1BXd19hTmtuT1hrV0dqZ3dDN1JkNVRDdzJsZ2tOQ3RTWHJ6R01sZVljNWNsMTkwZlo1bTdNMXVUT05iSHFXNTRuVm5NZW…

Google News ue, 25 Aug 2026

Entero Healthcare shares gain 15% in 2 days after Prashant Jain’s 3P Investment picks stake in block deal - The Economic Times

<a href="https://news.google.com/rss/articles/CBMiiAJBVV95cUxPSDJ6M0FJTzJQTGIzbTRDZUxXcWk2b2hOeHNodmpuSkFZR0F4SGhxZGozV0FTWllDQWdMRzZ6bXdEU1FIWnh5UWxNT3VfTE4zX3M3ZmZfN0xqaHRLZWRjcjdTenBTLXJGek4yYk80Z3ZnVTJpVTc0c05JWVNDRjJfYmtKNzg3bl9oSk1YaU…

Google News ue, 01 Sep 2026

Entero Healthcare Shares In Focus As ICICI Securities Initiates With 'Buy' Rating — Check Target Price - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQanR2Mml3LXg2UkViYVJBcUVBZGhwLVJMeE8taTNlZXpvdG5ZLUZzekJfYWczdnRRenJ0dmlvcU0yNkVZS1Q2cUZVU193dUtHcUxNRnZEcjNsRlZxelFlZzNGbWxRa0wxdDNJbUVXdkJ1NFZDelEwZE1tQWFKMDM0YnlteFEyZGRFb3NNbm…

ENTERO — Frequently Asked Questions

What is the current share price of Entero Healthcare Solutions Limited (ENTERO)?

As of 2026-09-08 04:53 IST, Entero Healthcare Solutions Limited (ENTERO) trades at ₹1,827.60 on NSE. Its 52-week range is ₹949.20 to ₹1,848.00.

What is the market capitalisation of ENTERO?

Entero Healthcare Solutions Limited (ENTERO) has a market capitalisation of ₹7,952.06 Cr on NSE.

What is the P/E ratio of ENTERO?

ENTERO trades at a trailing price-to-earnings (P/E) ratio of 83.99. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 3.20.

What is the return on equity (ROE) of ENTERO?

ENTERO has a return on equity (ROE) of 6.81%. Its return on capital employed (ROCE) is 11.35%.

Is ENTERO a good stock to buy?

This page provides a data-driven analysis of Entero Healthcare Solutions Limited (ENTERO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space